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Abstract
The adult quiescent blood–brain barrier (BBB), a structure organised by endothelial cells through interactions with pericytes, 
astrocytes, neurons and microglia in the neurovascular unit, is highly regulated but fragile at the same time. In the past dec-
ade, there has been considerable progress in understanding not only the molecular pathways involved in BBB development, 
but also BBB breakdown in neurological diseases. Specifically, the Wnt/β-catenin, retinoic acid and sonic hedgehog path-
ways moved into the focus of BBB research. Moreover, angiopoietin/Tie2 signalling that is linked to angiogenic processes 
has gained attention in the BBB field. Blood vessels play an essential role in initiation and progression of many diseases, 
including inflammation outside the central nervous system (CNS). Therefore, the potential influence of CNS blood vessels 
in neurological diseases associated with BBB alterations or neuroinflammation has become a major focus of current research 
to understand their contribution to pathogenesis. Moreover, the BBB remains a major obstacle to pharmaceutical interven-
tion in the CNS. The complications may either be expressed by inadequate therapeutic delivery like in brain tumours, or by 
poor delivery of the drug across the BBB and ineffective bioavailability. In this review, we initially describe the cellular and 
molecular components that contribute to the steady state of the healthy BBB. We then discuss BBB alterations in ischaemic 
stroke, primary and metastatic brain tumour, chronic inflammation and Alzheimer’s disease. Throughout the review, we 
highlight common mechanisms of BBB abnormalities among these diseases, in particular the contribution of neuroinflam-
mation to BBB dysfunction and disease progression, and emphasise unique aspects of BBB alteration in certain diseases 
such as brain tumours. Moreover, this review highlights novel strategies to monitor BBB function by non-invasive imaging 
techniques focussing on ischaemic stroke, as well as novel ways to modulate BBB permeability and function to promote 
treatment of brain tumours, inflammation and Alzheimer’s disease. In conclusion, a deep understanding of signals that 
maintain the healthy BBB and promote fluctuations in BBB permeability in disease states will be key to elucidate disease 
mechanisms and to identify potential targets for diagnostics and therapeutic modulation of the BBB.
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The BBB under steady state conditions
Introduction
The blood–brain barrier (BBB) is instrumental in estab-
lishing and maintaining the microenvironment of the cen-
tral nervous system (CNS) that permits proper neuronal 
function. Since the establishment of the BBB concept by 
Paul Ehrlich, Edwin Goldmann and Lena Stern about a 
century ago, the morphological, molecular and physiologi-
cal properties of the BBB have been extensively studied. 
Although the pioneering work of Reese and Karnovsksi as 
well as Brightman and Reese in the late 1960s identified 
that CNS endothelial cells (ECs) are the site of the BBB 
proper, it has become apparent that ECs require contacts 
with various CNS cell types to establish BBB character-
istics (for review see [27]). The close contact of ECs with 
pericytes (PCs) via the “peg-and-socket” junctions within 
a common basal lamina and the ensheathment of brain 
capillaries by astrocytic endfeet are crucial for establish-
ing and maintaining the BBB [24]. Moreover, interneurons 
and perivascular microglia also make contacts with ECs, 
pericytes and astrocytes to establish a neuro-vascular unit 
Fig. 1  Morphological and functional characteristics of the healthy 
NVU and BBB. a Scheme of brain vessels ranging from an arteri-
ole, via a capillary to a venule, representing the cellular and molecu-
lar composition of the NVU. b Isolated mouse cortical micro vessel 
stained for CD31, desmin, Aqp4 and DAPI. Due to the mechanical 
and chemical isolation process, only remnants of PCs and AC end-
feet are detectable at the CD31  +  vessel. c Mouse cortical vessels 
stained in vibratome sections for CD31, CD13 and Aqp4, demonstrat-
ing almost complete coverage of vessels by AC endfeet. PCs indi-
cated by arrowheads are located on microvessels and cling around 
them with their cellular processes. d Magnified ROI of C and 3D ren-
dered, demonstrating partially incomplete astrocytic endfeet coverage 
of endothelial cells (asterisks) as well as PC cell body (arrowheads) 
and processes (arrows). e Transmission electron microscopy show-
ing a cortical capillary with ECs, PCs and ACs with interendothe-
lial junctions (lower panel). Higher magnification of interendothelial 
junctions (upper panel) (kindly provided by Jadranca Macas, Insti-
tute of Neurology, Goethe University Clinic Frankfurt, Germany). f 
Freeze fracture preparation of a cortical capillary with an attached 
pericyte (lower panel). Freeze fracture of interendothelial junction 
(upper panel), arrowheads show junctional strands. Inset shows junc-
tion strands in higher magnification (kindly provided by Hartwig 
Wolburg, Institute of Pathology, University Clinic Tübingen, Ger-
many). ECs, endothelial cells; PCs, pericytes; SMCs, smooth muscle 
cells; ACs, astrocytes; MG, microglia
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(NVU) (Fig. 1a), a term that reflects both morphological 
relationships as well as molecular interactions between 
these various cell types.
However, not all CNS ECs share the same morphological, 
molecular and physiological characteristics. This regional 
vascular heterogeneity is probably best described for struc-
tures like the choroid plexus or the circumventricular organs 
(CVOs) whose blood vessels lack a BBB to allow secre-
tion of the cerebrospinal fluid and neurosecretory/-sensory 
function, respectively [113]. In recent years, it has become 
more evident that microvessels do not share identical bar-
rier features even within CNS regions that have a proper 
BBB [134]. Multiple genetic studies with global or condi-
tional transgenic mouse lines have identified that Wnt7a/7b 
ligands and the Wnt/β-catenin pathway are major molecular 
drivers of angiogenesis and barriergenesis in the brain [35] 
(Fig. 1a). The specificity of Wnt ligand binding and down-
stream pathway activation in the brain depend on specific 
co-receptors in ECs such as G-protein coupled receptor 
124 (Gpr124) [147] and reversion-inducing cysteine-rich 
protein with Kazal motifs (RECK) [25, 129]. However, the 
molecular players that activate the β-catenin pathway in the 
retina and cerebellum are quite distinct. Genetic ablation 
of the Norrin disease protein (Ndp) ligand, Wnt receptor 
Frizzled 4 (Fzd4), Lrp5 and the co-receptor Tetraspanin-12 
(Tspan-12) result in defective angiogenesis and barrier 
disruption in both retinal and cerebellar vessels [25, 148]. 
These studies demonstrate regional differences in both 
molecular and ultimately physiological aspects of the BBB 
within the CNS. Blood vessels in the retina, which form a 
blood–retina barrier (BRB), have also distinct PC attachment 
and astrocyte coverage from their brain counterparts [17]. 
Investigation of these regional differences is a major focus in 
current BBB research in order to identify relevant physiolog-
ical function of the BBB within specific CNS regions and to 
develop potential drug targets for neurological pathologies 
like ischaemic stroke, tumour, neuroinflammation, Alzhei-
mer’s diseases affecting certain CNS regions.
Below, we describe and discuss the BBB under steady-
state condition and selected pathologies of the brain, focus-
ing on ischaemic stroke, brain tumours, neuroinflammation 
and Alzheimer’s disease to illustrate the cellular and molecu-
lar mechanisms affecting BBB function in these diseases 
and identify potential diagnostic and therapeutic progress 
ultimately affecting patient survival.
Endothelial cells under steady‑state conditions
Brain ECs are characterised by elaborate tight junctions 
(TJs) that are formed primarily by the endothelial-specific 
claudin family member claudin-5 (Cldn5) and occlu-
din (Ocln) (Fig. 1a, e, f). These proteins are linked to the 
cytoskeleton by members of the zonula occludens family 
(ZO-1, -2, -3) (Fig. 1a). Cldn5 plays a crucial role for TJ 
formation and BBB paracellular function, since embryonic 
ablation of Cldn5 in mice leads to early postnatal brain 
oedema and lethality (reviewed in [35]). Moreover, Cldn5 
is regulated in vivo by the Wnt/β-catenin pathway in an 
opposing manner to that of the permeability associated pro-
tein plasmalemma vesicle-associated protein (Plvap; also 
known as Meca-32) (reviewed in [35]). However, Cldn5 
regulation by β-catenin appears to be highly context depend-
ent. Corada and colleagues have demonstrated that Cldn5 
is inhibited, rather than activated, by β-catenin when the 
transcription factor FOXO-1 that is normally induced by vas-
cular endothelial growth factor (VEGF) signalling is active 
in ECs. Thus, activation of other signalling pathways (e.g. 
VEGF) may counteract the ability of β-catenin signalling 
to regulate transcriptional targets important for BBB func-
tion (reviewed in [35]). Cldn5 overexpression does not lead 
to high resistant TJs in ECs in vitro, suggesting that other 
TJ proteins like Cldn3 and -12, play an important role to 
regulate the paracellular barrier of brain ECs [35]. How-
ever, the contribution to BBB function of these additional 
TJ-associated proteins and their structural and molecular 
integration is still under debate. Several studies have docu-
mented expression and regulation of Cldn3 in brain ECs 
in vitro and in vivo [126]; however, there is no direct evi-
dence that Cldn3 is required for BBB function. Recently, 
Cldn3 has been shown to be instrumental in maintaining 
blood–cerebrospinal fluid barrier (BCSF) in epithelial cells 
under chronic inflammatory conditions (reviewed in [126]). 
Further studies using endothelial-specific deletion of Cldn3 
or other members of the claudin family are needed to deter-
mine their contribution to BBB paracellular permeability. 
Members of the IgG superfamily such as EC adhesion mol-
ecule (ESAM), junction adhesion molecules (JAM1-3) and 
nectins are also associated with TJs, and have been shown to 
regulate TJs function as well as transmigration of inflamma-
tory cells, particularly leukocytes, across the endothelial bar-
rier [33]. However, their detailed function at the BBB is not 
fully established. Finally, a class of TJ-associated proteins 
such as tricellulin [53] and lipolysis-stimulated lipoprotein 
receptor (LSR) [79] are localised at the point of connection 
between three cells (so-called tricellular junctions), which 
are weak junctional points between cells. Tricellulins play 
an essential role to stabilise these specialised junctions in 
epithelial cells; however, their role at the BBB is unknown. 
Genetic deletion of LSR results in hampered formation of a 
proper paracellular endothelial barrier during development 
and increased leakiness to small molecules [114], suggest-
ing that these specialised tricellular junctions may play an 
important role at the BBB.
Although TJs regulate the paracellular endothelial bar-
rier properties, adherens junctions (AJs), formed by homo-
philic interactions between cadherins, are considered a 
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prerequisite for the establishment of TJs (for review, see  
[29]). Vascular endothelial (VE)-cadherin (Cdh5, CD144) 
is the major cadherin family member in ECs. N-cadherin 
is the second most expressed cadherin family member in 
ECs and mediates interaction between ECs and PCs via the 
peg-and-socket junctions. Although AJs are present in all 
ECs, their molecular composition and consequently their 
functional properties differ between distinct types of vessels 
[29]. Both VE- and N-cadherin function also as adhesion 
receptors and are involved in downstream signalling via a 
complex of proteins bound to their cytoplasmic tails. Beside 
its function as a co-transcription factor in the canonical Wnt 
pathway mentioned above, β-catenin and its close homo-
logue plakoglobin/γ-catenin promote VE-cadherin anchor-
age to actin microfilaments.
A second unique feature of the BBB is the presence of 
various facilitated and active transport mechanisms in ECs 
that confer nourishment of the CNS as well as transport of 
waste products out of the CNS. The best described trans-
porter is the glucose transporter isoform 1 (Glut-1, Slc2a1) 
that becomes highly expressed upon BBB formation and has 
been shown to be regulated by the Wnt/β-catenin pathway 
[35]. Among the plethora of transporters expressed in brain 
ECs, the thyroxine transporter, belonging to the solute car-
rier organic anion transporter family member (Slco1c1), has 
been exploited to drive brain endothelial-specific expres-
sion of the Cre recombinase as a valuable tool to investigate 
BBB-specific gene function [102]. BBB ECs also express 
members of the ATP-binding cassette family of transport-
ers, like Abcg1a1 (Mdr, Pgp), Abcg2 (Bcrp), Abcc1 (Mrp1) 
and others. The most intensively studied ABC transporter 
certainly is Pgp, that is a BBB identity gene, and has been 
implicated in barrier homeostasis and in the progression of 
various diseases like Alzheimer’s disease and others (for 
review see [83]).
A third feature of the BBB is the presence of a small num-
ber of caveolae and reduced transcellular transport [27, 35]. 
Recently, a transporter of the major facilitator superfamily 
domain-containing (Mfsd) family, specifically Mfsd2a has 
been characterised as a transporter for the essential omega-3 
fatty acid docosahexaenoic acid (DHA) in brain ECs that 
contribute to the regulation of vesicular traffic in CNS BBB/
BRB endothelia [12]. Interestingly, the expression of Mfsd2a 
becomes upregulated in CNS ECs along with the formation 
of BBB characteristics. Systemic gene ablation of Mfsd2a in 
mice resulted in BBB leakiness due to significantly increased 
vesicular traffic in ECs. Mfsd2a is located upstream of cave-
olin-1 (Cav-1) and regulates the membrane lipid composi-
tion of CNS ECs that in turn influences the formation of 
caveolar-rich domains within the membrane [26]. Cav-1 is a 
well-known marker of caveolae in endothelial cells and plays 
an important role in endothelial physiology and pathology, 
regulating functions like signal transduction, endocytosis, 
transcytosis, and molecular transport. Specifically, Cav-1 
regulated the angiogenic response by influencing VEGF 
receptor 2 (VEGFR2) phosphorylation and internalisation 
[145]. In the context of junctional opening, Cav-1 was shown 
to interact with β-catenin and to thereby weaken the VE-
cadherin-based AJs [64]. At the BBB, Cav-1 was described 
to relate to diminished TJ proteins expression upon BBB 
disruption. Cav-1 cooperates with several pathways, serving 
as a signalling platform. Genetic ablation experiments of 
Cav-1 revealed a major function for mediating transcellular 
but not paracellular permeability in BBB ECs.
Pericytes under steady‑state conditions
Genetic manipulations in mice that change the coverage of 
blood vessels by PCs have shown that PCs play a crucial 
contribution to BBB integrity, in particular via the regula-
tion of the transcellular barrier [124]. Genetic ablation of 
Mfsd2a and PC vessel coverage do not affect TJs integrity 
and suggest that the paracellular BBB pathway is regulated 
independently from the transcellular pathway. Recent stud-
ies from Chow and Gu have shown that BRB maturation is 
controlled by down regulation of vesicular transport (tran-
scellular permeability), rather than by improvement in the 
junctional seal between ECs (paracellular barrier) [26], sup-
porting the independent regulation of the two pathways that 
control BBB/BRB function. PCs are the cells of the NVU 
most firmly attached to the endothelium, and as cellular 
“relatives” of smooth muscle cells they may regulate ves-
sel diameter, thereby controlling physiological parameters 
of blood supply [124], although these findings are contro-
versial. One way in which PCs communicate with ECs are 
via the “peg-and-socket” junctions which are formed by 
N-cadherin and connexin-43 hemichannels, and may allow 
transport of nutrients and signalling metabolites [124]. How-
ever, it is not clear how PCs communicate with ECs and 
which are the molecular regulators involved in this mutual 
interaction. Chen et al. have recently shown that the single 
cell adhesion receptor CD146 (syn.: melanoma cell adhesion 
molecule (MCAM) or cell surface glycoprotein MUC18) 
functions as a co-receptor for PDGFR-β on PCs to regulate 
PC-EC interactions [23]. Interestingly, CD146 is differen-
tially expressed during BBB maturation, showing initial 
expression on ECs that are devoid of PCs, followed by its 
endothelial downregulation upon PC recruitment and BBB 
maturation. The latter happens to be promoted by TGFβ-1 
secretion upon PCs attachment. Although several stud-
ies have shown that PCs are essential for BBB formation 
and maintenance, astrocytes (ACs) are also considered as 
a major source for barrier inducing and maintaining sig-
nals [24]. It is conceivable that CNS-intrinsic cues, includ-
ing those released from astrocytes, might be required to 
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complete and/or supplement the barrier-promoting signals 
derived from PCs.
Astrocytes under steady‑state conditions
Astrocytes (ACs) are the most numerous cell type in the 
vertebrate CNS and their specialised end-feet cover nearly 
the entire surface of CNS microvessels. ACs develop 
at late gestation stages (mouse ~ E17.5) from radial glia 
(RG) and common neural precursor cells (NPC), suggest-
ing that early BBB-inducing events are likely not mediated 
by ACs [24]. However, ACs are in close association with 
brain microvessels and various AC proteins like aquaporin-4 
(Aqp4) and the potassium channel Kir4.1 are localised at 
the end foot membrane to regulate water homeostasis at 
the NVU (Fig. 1b, c, d) (for review see [35]). Moreover, 
Aqp4 has been implicated in the flow of the interstitial fluid 
(ISF) as part of the so-called “glymphatic system” (dis-
cussed in detail in the manuscript by Abbott et al. in this 
cluster). ACs improve endothelial barrier function either in 
co-culture models or by the administration of conditioned 
medium to the EC single cultures in vitro [24]. Moreover, 
postnatally ACs are the major source of Wnts and norrin that 
were identified as crucial factors of BBB maintenance [148]. 
Additionally, ACs secrete sonic hedgehog (Shh), retinoic 
acid (RA) and angiopoietin-1 (Ang-1), all key factors that 
induce or support barrier properties of brain ECs [5, 43]. 
AC–EC interactions are essential not only for the establish-
ment and maintenance of the BBB, but also for astrocyte 
differentiation. ECs secrete factors like leukaemia inhibi-
tory factor 1 (LIF1) that supports ACs differentiation. This 
in turn induces expression of Src-supressed C-Kinase sub-
strate (SSeCKS), leading to the astrocytic secretion of Ang-1 
that stabilises vessels through Tie2/TEK binding on ECs 
(reviewed in [35]). It is not entirely clear which AC-derived 
factors including interleukin-6 (IL-6), glial cell line-derived 
neurotrophic factor (GDNF) or fibroblast growth factor 2 
(bFGF) are crucial for BBB maturation and maintenance. 
Hence more work needs to be done to unravel the molecular 
crosstalk not only between ECs and ACs, but also between 
PCs and ACs.
Neurons, microglia and extracellular matrix 
components under steady‑state conditions
Since ACs develop during late embryonic and postnatal 
stages to support BBB maintenance, but not induction, 
neural precursor and early neurons were shown to be the 
main source of Wnt7a and Wnt7b that promote brain vas-
cularization and the formation of the BBB (for review see 
[35]). Once the NVU is fully established and the BBB is 
mature, neurons do not or infrequently have direct contact 
with brain ECs, suggesting that ACs and PCs may take over 
for BBB maintenance. However, both PCs and ACs directly 
signal to neurons to modulate synaptic strength and also 
convey signals from neurons to the vasculature, ultimately 
leading to arteriolar dilation and an increase in local blood 
flow, thereby influencing BBB physiology [10]. Microglia 
are abundant resident immune cells in the CNS that display 
little turnover under physiological conditions. Due to their 
perivascular localisation they screen the brain parenchyma 
for blood-borne substances and potential inflammatory stim-
uli, providing a first line of defence in the CNS [120]. During 
brain angiogenesis, microglia and macrophages have been 
implicated in the regulation of vascular growth, by secretion 
of attractive as well as repellent signals including Wnts (for 
review see [35]). Once vascularisation is completed and the 
BBB is established, the role of the resident microglia for 
BBB maintenance is less clear, given the fact that postnatal 
ablation of microglia does not result in BBB impairment 
[120]. Hence the role of microglia under steady-state condi-
tions at the BBB has to be investigated in more detail.
The extracellular matrix (ECM) components at the BBB 
are also crucial for its establishment and integrity [9]. ECs 
are embedded in a common basement membrane (BM) with 
PCs; both cell types contribute to secretion of components 
like collagen IV and fibronectin, as well as laminin 411 
(α4β1γ1), laminin 511 (α5β1γ1) and laminin 211 (α2β1γ1). 
Astrocytes, however, secrete laminin 111 (α1β1γ1) and 211 
(α2β1γ1), as well as nidogen, perlecan and agrin [9]. Agrin 
is considered to have important function in establishing and 
maintaining AC end foot polarisation and consequently 
Aqp4 clustering in orthogonal arrays of particles (OAPs). 
The main receptors of ECM components are dystroglycan 
as well as members of the integrin family of adhesion recep-
tors. Genetic ablation experiments in mice have revealed 
that integrin αvβ8 leads to haemorrhages in the brain, likely 
by inhibiting TGFβ-mediated EC differentiation [9]. This 
finding also nicely illustrates that the ECM is a rich source 
for growth factors like latent TGFβ binding protein (Ltbp), 
VEGF, Wnts and other growth factors. To further unravel 
the specific role of ECM components at the BBB and their 
involvement in BBB maintenance, additional cell-specific 
and inducible loss- and gain-of-function approaches in mice 
need to be conducted.
In vivo imaging of blood–brain barrier 
permeability after ischaemic stroke
Stroke, caused by interrupted blood flow to the brain, is 
among the leading causes of death and disability worldwide. 
Over the past two decades, treatment options for ischae-
mic stroke—the major stroke subtype—have substantially 
improved with the availability of clinically approved strat-
egies to induce reperfusion of ischaemic brain tissue, i.e. 
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intravenous pharmacological thrombolysis with recombi-
nant tissue plasminogen activator (rt-PA) or endovascular 
mechanical thrombectomy. However, despite their potential 
to salvage affected brain tissue and to improve functional 
outcome after acute ischaemic stroke, these reperfusion ther-
apies are hampered by a relatively short therapeutic time-
window of a few hours because of risk of bleeding.
Haemorrhagic transformation after ischaemic stroke is 
typically preceded by disruption of the blood–brain barrier 
(BBB). BBB leakage develops in the first hours after stroke 
and may contribute to progression of ischaemic tissue dam-
age, secondary neuro-inflammation, vasogenic oedema for-
mation and intracerebral bleeding [142]. Timely reperfusion 
may restore BBB permeability; however, late reperfusion 
can aggravate BBB injury, as a consequence of production 
of reactive oxygen species (ROS) and release of proteases 
[e.g. matrix metalloproteinases (MMPs)] from infiltrated 
leukocytes [56, 142]. This implies that the time and extent of 
BBB disruption are critical factors in the outcome of spon-
taneous or therapeutically induced reperfusion after stroke. 
Characterization of the BBB status can therefore provide 
valuable information on the condition and fate of ischaemic 
brain tissue, and may aid in treatment decision-making and 
monitoring following acute ischaemic stroke.
Over the years, several in vivo imaging methodologies 
have been developed to measure the integrity of the BBB. 
Magnetic resonance imaging (MRI), computed tomogra-
phy (CT)/single-photon emission computed tomography 
(SPECT), or optical imaging, combined with intravenous 
injection of paramagnetic, radiolabelled or fluorescent mark-
ers, respectively, enable detection of contrast agent leakage 
across the BBB. The following sections will describe how 
different imaging approaches can inform on the degree, pat-
tern, origin and consequences of BBB injury in clinical and 
experimental studies.
MRI of BBB leakage after stroke
MRI of BBB leakage is determined from the extravasation 
and subsequent tissue accumulation of intravenously injected 
paramagnetic contrast agent, typically gadolinium (Gd)-
based media, such as Gd-diethylenetriaminepentaacetic acid 
(Gd-DTPA). Parenchymal Gd-induced signal enhancement 
on  T1-weighted MR images early after thrombolytic therapy 
has been shown to be predictive of subsequent symptomatic 
intracerebral haemorrhage in acute ischaemic stroke patients 
[49, 80]. In an embolic stroke model in rats, it was found that 
clear Gd-induced  T1-weighted signal intensity enhancement, 
which preceded post-treatment bleeding, was already detect-
able before rt-PA treatment, particularly in regions with low 
CBF [32].
While severe focal BBB leakage can lead to haemor-
rhagic transformation after thrombolysis, mild diffuse BBB 
permeability may be reversible upon early reperfusion [112]. 
Small and transient increases in BBB permeability, detect-
able with dynamic contrast-enhanced (DCE) MRI (see also 
the next section on quantification of BBB permeability), 
may even occur outside the ischaemic territory during the 
first days after stroke [130]. Furthermore, MRI-based meas-
urement of BBB leakage in contralesional white matter of 
acute ischaemic stroke patients has been found to be associ-
ated with elevated plasma MMP-2 levels and loss of micro-
structural white matter integrity (Fig. 2) [104]. Remote and 
widespread BBB leakage may reflect diffuse microvascular 
dysfunction, which could contribute to poor outcome after 
stroke. This indicates the potential of whole-brain imaging 
of BBB permeability as a complementary measure for the 
diagnosis of acute ischaemic stroke patients with possible 
microangiopathy. Interestingly, at later stages, MRI of BBB 
permeability may provide insights in post-stroke vascular 
remodelling or angiogenesis, possibly associated with func-
tional recovery, as demonstrated in rodent studies [55].
Post-contrast MR images are usually acquired within 
30 min after contrast agent injection, i.e. in the same scan-
ning session. However, late gadolinium enhancement of cer-
ebrospinal fluid space can be observed on follow-up fluid-
attenuated inversion recovery (FLAIR) MR images of acute 
ischaemic stroke patients [66]. This phenomenon is strongly 
related to reperfusion and has, therefore, been termed 
“hyperintense acute reperfusion marker” (HARM). HARM 
has been recognised as a sign of early BBB breakdown and 
reperfusion injury, and its occurrence after thrombolysis has 
been associated with a higher incidence of post-procedural 
haemorrhages and worse neurological recovery [66].
Quantification of BBB permeability
Detection of signal enhancement on post-contrast images 
is the most straightforward way to identify regions with a 
leaky BBB. In addition to this qualitative assessment, BBB 
permeability can be quantified with DCE or perfusion imag-
ing protocols on MRI or CT scanners.
For DCE imaging, MR or CT images are serially acquired 
before, during and after injection of a low-molecular weight 
paramagnetic or iodinated contrast agent, respectively. The 
efflux rate of contrast agent from blood plasma into the tis-
sue extravascular extracellular space, i.e. the volume transfer 
constant,  Ktrans (or blood-to-brain transfer constant,  Ki), or 
permeability-surface area product (PS), can be calculated 
from pharmacokinetic modelling of DCE signal intensity 
changes [117]. Common models are based on exchange 
between intra- and extravascular compartments. A popular 
analysis approach involves the Patlak plot model, a graphical 
analysis method that has been successfully validated in a rat 
stroke model [37], which appears particularly suitable for 
detection of subtle BBB permeability [48].
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T2*-weighted dynamic susceptibility contrast-enhanced 
(DSC) MRI or dynamic CT perfusion imaging are routinely 
used for measurement of haemodynamic indices, but also 
allow calculation of parameters, such as relative recircula-
tion, that have been shown to be related to BBB integrity 
[139]. Although spatial resolution is usually lower than with 
DCE MRI, a major advantage of these rapid imaging meth-
ods is their short acquisition time (typically less than two 
minutes). In a multicentre retrospective study, permeability 
measures derived from DSC MRI in acute ischaemic stroke 
patients were found to provide an average haemorrhage 
prediction accuracy of more than 85% [107]. Similarly, 
increased PS values calculated from dynamic CT perfu-
sion data have been shown to be predictive of haemorrhagic 
transformation in acute ischaemic stroke patients [71].
Different contrast agents for BBB assessment
Diverse contrast agents with different dimensions and 
pharmacodynamic properties are available for assessment 
of BBB disruption. Although most of these agents are not 
approved for clinical use, they can be employed to experi-
mentally investigate details and dynamics of BBB dys-
function in animal models. Application of contrast agents 
that differ in size enables assessment of varying BBB pore 
dimensions [146], while contrast agents with a long circu-
lation life-time allow longitudinal monitoring of the evolu-
tion of BBB breakdown [32, 72]. For example, with MRI-
detectable superparamagnetic long-circulating micron-sized 
iron oxide particles it was demonstrated that late delivery 
of rt-PA after embolic stroke in rats may rapidly incite 
extravasation of the circulating iron oxide particles, reflec-
tive of abrupt aggravation of microvascular barrier injury 
(see [32]). Build-up of iron oxide particles (or other micro- 
or nano-probes) in acute ischaemic tissue probably mostly 
results from passive diffusion through disrupted BBB [30]; 
however, intravenously injected iron oxide particles may 
also be taken up by (circulating) phagocytes, enabling MRI-
based detection of inflammatory cells accumulating in or 
around ischaemic lesions [28]. This becomes particularly 
Fig. 2  Imaging BBB permeability after stroke—from microscopic 
detection in mice to whole-brain assessment in patients. a Two-
photon microscopic imaging, pre and post photothrombotic vessel 
occlusion, showing post-stroke capillary BBB leakage (green arrow) 
occurring particularly at pericyte somata (red arrow) in mouse brain 
(kindly provided by Robert Underly and Andy Shih, Medical Univer-
sity of South Carolina, Charleston, SC, USA) (for details see [127]). 
b MRI of increased BBB leakage rate (right image; colour coding) 
in contralesional white matter in a patient with an acute unilateral 
ischaemic stroke lesion (left image; hyperintensity on perfusion MRI-
derived mean transit time map) (kindly provided by Ona Wu, Massa-
chusetts General Hospital and Harvard Medical School, Boston, MA, 
USA) (Reprinted by Permission of SAGE Publications, Ltd.) (for 
details see [104])
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prominent at subacute stages after stroke when cellular infil-
tration is highest.
The availability of a variety of fluorescent vascular trac-
ers also renders optical imaging methods applicable for 
in vivo studies on BBB dysfunction in animal models. In 
mice, time-domain near-infrared fluorescent (NIRF) imag-
ing of optical tracers with different molecular weights has 
shown that the BBB is open to leakage of small as well as 
large molecular tracers at 24 h after 60-min middle cerebral 
artery occlusion (MCAo) [2]. Furthermore, in the same 
study bilateral and biphasic BBB disruption was observed 
with longitudinal NIRF of a small intravascular tracer dur-
ing the first week after 30 min MCAo, which resolved after 
14 days. The dynamics of BBB permeability after acute 
ischaemic stroke remain incompletely understood. Bipha-
sic opening in relation to ischaemia–reperfusion injury has 
been frequently described [142], while there are also (MRI) 
reports of continuous BBB leakage from acute to suba-
cute or chronic stages after (transient) cerebral ischaemia 
in rodents and human patients (for review see [80]). In a 
study that combined MRI and NIRF imaging in mice that 
underwent 60-min MCAo, co-injection of Gd-DTPA and 
bovine serum albumin (BSA)-conjugated indotricarbocya-
nine revealed dissimilar extravasation patterns for the two 
contrast agents [60]. Gd-DTPA enhancement was detected 
at all time-points, whereas accumulation of the NIRF tracer 
was biphasically apparent at 8 and 16 h after reperfusion. 
These findings highlight the effect of contrast agent features, 
such as molecular weight and pharmacodynamics (BSA con-
jugates have relatively long plasma half-lives), on the leak-
age profile and time-course.
Most contrast agents are not approved for clinical use and 
even clinically approved contrast agents may have negative 
side effects. It is now well recognised that Gd-DTPA, which 
is primarily cleared by the kidneys, can cause nephrogenic 
system fibrosis and renal complications in patients with 
kidney disease [3]. Consequently, there is growing interest 
in imaging methods that can measure transvascular transfer 
in the brain without the use of contrast agents. For exam-
ple with magnetization transfer-based MRI, where shifts 
between free and protein-bound water pools, measured from 
altered  T1 relaxation time in the presence of off-resonance 
radiofrequency saturation  (T(1sat)), may be indicative of leak-
age across the BBB [61]. MRI methods that enable quanti-
fication of transvascular water exchange based on perfusion 
and diffusion measurements have also been proposed [132]. 
These promising studies require further follow-up investi-
gations to determine the sensitivity, specificity and clinical 
applicability of these contrast agent-free MRI methods for 
accurate and reliable detection of BBB permeability.
Microscopic imaging of BBB dysfunction
As described above, MRI, CT and NIRF imaging can pro-
vide whole-brain information on BBB integrity, but spa-
tial resolution is limited to macroscopic scales. However, 
microscopic assessment of BBB permeability is feasible 
with optical imaging in laboratory animals, in which small 
vessels are visualised on the cortical surface through a 
cranial window. With real-time fluorescence imaging, the 
extravasation of an impermeable fluorescent tracer from 
small cortical surface vessels has been measured in per-
ilesional tissue as early as 30 min after cerebral ischaemia 
in rats [96]. An important advantage of intravital fluores-
cence imaging is the possibility of combined detection of 
cellular and molecular events that can provide insights into 
mechanisms that underlie BBB disruption. With longitudinal 
in vivo fluorescent angiography and parallel measurements 
of fluorescent markers of reactive oxygen/nitrogen species 
and cellular injury, Schoknecht et al. showed that propaga-
tion of vascular permeability within peri-ischaemic rat brain 
tissue is associated with free radical formation and progres-
sive cell damage [109]. Even more detail can be obtained 
with two-photon microscopy, as recently demonstrated by 
Underly et al. who reported a central role of pericytes in 
early ischaemia-induced BBB disruption [127]. In transgenic 
mice with fluorescently labelled pericytes they observed that 
capillary BBB leakage after photo-thrombotic occlusion was 
preceded by MMP activation—visualised with a fluorescent 
probe for MMP-2/9 activity—occurring particularly at peri-
cyte somata sites (Fig. 2a). Studies with transgenic mice 
where tight junctions are labelled with eGFP (Tg: eGFP-
Claudin5 mice) have provided a detailed analysis of changes 
in structural components of the BBB in brain capillaries with 
in vivo two-photon microscopy in healthy and diseased brain 
(Fig. 4a) [62]. Dynamic imaging of tight junction turnover at 
the BBB in ischaemic stroke has demonstrated that although 
BBB function is impaired as early as 6 h after ischaemic 
stroke, TJs break down only 48 h after vessel occlusion in 
the transient middle cerebral artery occlusion (t-MCAO) 
model. These findings suggest that transcytosis impairs 
BBB function in the acute (within 6 h) phase of ischaemic 
stroke, whereas breakdown of TJs and increased paracellular 
permeability of CNS endothelium occurs in the late phase 
(24–48 h) following ischaemic stroke [62].
Taken together, various imaging methodologies have 
been established for qualitative and quantitative assessment 
of BBB permeability in stroke patients and animal mod-
els. Applications ranging from microscopic measurements 
in mice to whole-brain analyses in humans have improved 
our knowledge on patterns of BBB breakdown following 
cerebral ischaemia–reperfusion (Fig. 2). BBB permeability 
imaging methods are now being considered as complemen-
tary tools for diagnosis and outcome prediction in stroke 
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patients, for example to guide reperfusion therapies that are 
accompanied by increased risk of haemorrhagic transfor-
mation. In vivo imaging methods that enable detection of 
additional disease markers at the level of the neurovascular 
unit can provide important complementary information on 
the pathophysiological consequences of cerebrovascular 
injury. For example, imaging strategies that allow in vivo 
detection of molecular targets, e.g. upregulated cell adhesion 
molecules with MRI [28], or multimodal SPECT/CT [125], 
have shown promise in assessment of (neuro) inflammation 
associated with stroke and BBB injury. Furthermore, pre-
diction of ischaemic tissue fate has been shown to improve 
by including multiple imaging-based measures of ischae-
mia–reperfusion injury [15, 86]. The ongoing advances in 
imaging technologies will continue to enable original trans-
lational studies in experimental and clinical settings that will 
increase our understanding of the critical role of the BBB 
in stroke pathology and recovery, ultimately contributing to 
improved patient care.
Cancer‑mediated dysfunction of the blood–
brain barrier
Brain cancer biology
Many neurological disorders including brain tumours are 
almost always associated with increased vascular permeabil-
ity, potentially leading to life threatening cerebral oedema 
[35]. Brain tumours represent a heterogeneous group of 
central nervous system (CNS) neoplasms that are classified 
into primary or secondary brain tumours according to their 
origin, i.e. intracerebral or spread from peripheral tumours 
[74]. The two most common types if intracranial neoplasms, 
brain metastasis and IDH wild type glioblastoma, account 
for > 70% of all brain tumours. Diffuse gliomas including 
IDH wild type glioblastoma, are the most common neuro-
ectodermal tumours that arise in the white matter of the 
cerebral hemispheres and are characterised by infiltrative 
growth [74]. The progression of gliomas is highly angiogen-
esis-dependent [98]. As a consequence of unphysiological 
angiogenesis the BBB is disturbed. VEGF signalling has 
been identified as the principal regulator of developmen-
tal and pathological angiogenesis which led to the devel-
opment of anti-angiogenic cancer therapies in 2004 [39]. 
More recently, Angiopoietin (Ang)/Tie2 signalling which 
regulates vascular development, maturation and immediate 
vascular responses, has emerged as a novel vascular drug 
target in tumours, including glioma [106, 110]. Both angio-
genic signalling pathways are well known to interfere with 
endothelial barrier properties [101, 106]. Disease progres-
sion of low-grade to high-grade glioma (WHO grade II–IV) 
is characterised by increased vascularization associated with 
BBB disturbances. BBB alterations are most prominent in 
glioblastoma multiforme (WHO IV, GBM), the most malig-
nant brain tumour that is associated with high morbidity 
and poor median survival [74]. The current standard treat-
ment for newly diagnosed GBM which includes maximal 
surgical resection followed by combined radiochemotherapy 
with temozolomide, does not extend overall survival beyond 
15 months (for review see [98]). Anti-angiogenic therapy 
with Bevacizumab, a VEGF-targeting monoclonal antibody, 
is approved in a small number of countries for the treatment 
of recurrent GBM [98]. However, VEGF-targeting did not 
extend overall survival in first-line therapy [98]. Although 
intrinsic resistance mechanisms to anti-angiogenic therapy 
have been identified, unsuccessful drug delivery across the 
BBB may contribute to inefficient therapy [128]. The GBM 
microenvironment consists of highly specialised niches, such 
as the perivascular, the hypoxic-perinecrotic and the invasive 
niche at the tumour border which each display different BBB 
properties [45] (Fig. 3a). In the tumour centre, excessive 
vascular growth that is accompanied by severe hypoxia and 
necrosis due to elevated oxygen demands, leads to promi-
nent BBB defects [98, 128]. At the tumour border, invasive 
glioma cells migrate along vessels that have yet a mostly 
intact BBB (Fig. 3a) [45, 137].
Vessel architecture in glioma
GBM vessels are tortuous, disorganised and permeable with 
defective pericyte coverage and an abnormal basement mem-
brane [98] indicative for a BBB breakdown. Characteristic 
features of the aberrant GBM microvasculature are hyper-
plasia and vascular sclerosis („glomeruloid tufts“with mul-
tilayered, proliferating ECs) [98]. VEGF signalling through 
its receptors (VEGFRs) was identified as the key driver 
for vascular growth in GBM more than 2 decades ago [39, 
95]. VEGF is upregulated in hypoxic niches due to oxygen 
deprivation and secreted by pseudopalisading tumour cells 
which are aligned around necrotic cores [39, 95, 98]. In the 
hypoxic niche, vessels are obstructed and often collapsed as 
a result of vasogenic oedema. Vessels are hyperplastic which 
is associated with aberrant blood flow and a dysfunctional 
BBB. At the molecular level VEGF-induced BBB disrup-
tion in rodent GBM models is constituted by endothelial-
cell fenestrations, gaps and frequent numbers of caveolae 
[103]. Breakdown of the BBB is commonly characterised 
by a disturbed organisation of EC junctions rendering ECs 
permeable [137]. In peripheral vessels, VEGF-induced vas-
cular permeability is mediated by VEGFR2 phosphorylation 
(Tyr 494 in rodents and Tyr 951 in humans, respectively) 
and VE-cadherin endocytosis (see [39]). In the brain, EC 
integrity is further dependent on the proper organization 
of tight junction molecules. A selective loss of claudins in 
GBM vessels (claudin-1, -3 in microvessels and claudin-5 
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in hyperplastic vessels) indicates their role as central medi-
ators of barrier integrity and vascular permeability [137]. 
The chronic vascular hyperpermeability in GBM reflects 
the growth of structurally abnormal and immature vessels 
that are, among the described junctional defects, also defi-
cient in pericytes [35] which will be further discussed in 
the section below. In addition, further cellular components 
of the neurovascular unit (NVU) that contribute to aberrant 
BBB features in GBM are astrocytes by means of loss of 
astroglial polarity [137]. Recently, invading glioma cells at 
the single cell level have been shown to be able to disrupt 
the BBB in mouse GBM via astrocyte-vascular uncoupling 
[133]. As mentioned above, Wnt/β-catenin signalling which 
plays an essential role in BBB formation and maintenance 
in the healthy CNS has been shown to regulate vascular qui-
escence and barrier function in GBM via upregulation of 
platelet-derived growth factor B (PDGF-B) and mural cell 
recruitment [100]. Wnt/β-catenin signalling hence represents 
a valuable therapeutic target for anti-angiogenic and oedema 
therapy.
Angiogenic signalling and vascular integrity 
in gliomas
VEGF promotes neovessel formation in conjunction with 
EC-derived Ang-2 [39, 50, 101, 106]. Ang-2, an early GBM 
vessel marker [122], has recently-been identified as a resist-
ance factor to VEGF monotherapy in GBM [110]. Upon 
Ang-2 upregulation, Ang-1-mediated Tie2 phosphorylation 
is prevented, resulting in immature, permeable vessels [101, 
106, 110]. Improper NVU composition and functioning 
caused by high VEGF levels contribute to vessel perme-
ability in GBM, and upon recurrence often lead to life threat-
ening oedema [98]. Studies following VEGF monotherapy 
or combined VEGF/Ang-2 targeting in preclinical GBM 
models demonstrated a more normalised vasculature [106, 
Fig. 3  Schematic representation of the glioblastoma microenviron-
ment. a Glioblastoma defining niches are displayed. Perivascular 
niche: Glioma and tumour stroma cells create a specialised vascular 
niche. Macrophages are the most abundant population that support 
the tumour growth by releasing pro-angiogenic factors. Hypoxic/peri-
necrotic niche: Necrotic areas are characterised by pseudopalisad-
ing cells and high levels of hypoxia which recruit tumour supporting 
macrophages. Invasive tumour border: Glioma cells are traversing the 
blood vessels. Peripheral blood vessels preserve intact blood–brain 
properties in contrast to the tumour vasculature which is leaky. b 
Combining anti-VEGF therapy with Ang-2 blockade acts synergisti-
cally on vascular normalisation. Immunofluorescence staining with 
antibodies directed against Collagen IV (red) and desmin (green) on 
vibratome sections of GL261 glioma bearing mice, untreated and 
after dual anti-VEGF (Aflibercept) and Ang-2 inhibition (Trebananib)
321Acta Neuropathologica (2018) 135:311–336 
1 3
110]. Previously immature glioma vessels with a defective 
BBB/NVU that lack pericytes are consequently reverted to a 
more “normal“, pericyte-rich phenotype as a consequence of 
increased Tie2 signalling (Fig. 3b; [110]). Activation of the 
Ang-1/Tie2 axis is critical in order to achieve a mature vas-
culature during, both developmental and pathological angio-
genesis [101, 106]. Pericytes have previously been shown to 
be essential for proper BBB functioning [27]. Evidence in an 
Ang-2 gain-of-function (GOF) mouse model demonstrated 
a leaky BBB as the result of Ang-2-mediated pericyte-defi-
ciency, defective interendothelial junctions, increased num-
bers of vesicles and a disrupted glycocalyx [43]. Similarly, 
in the peripheral tumour vasculature, Ang-2 overexpres-
sion decreased endothelial integrity, while Ang-2 blockade 
improved EC junctions and basement membrane contacts 
of metastasis-associated lung capillaries [51]. In a preclini-
cal GBM model (GL261) in Ang-2 GOF mice, increased 
IgG permeability and hypoxia were evident and reversed 
upon anti-angiogenic VEGF and Ang-2 therapy [110] or by 
using a bi-specific Ang-2/VEGF-targeting approach [106]. 
Moreover, in other models with a disrupted BBB such as 
cerebral ischaemia, activation of Tie2 via inhibition of the 
vascular-endothelial phoshotyrosine phosphatase (VE-PTP) 
which interferes with Tie2 phosphorylation in the absence 
of VE-cadherin, promoted junctional stabilisation of cer-
ebral vessels [43]. VE-PTP inhibition has been shown to 
be effective in ocular diseases, metastasis and permeability 
models and clinical trials are currently pursued for macula 
oedema [18]. In GBM, VE-PTP inhibition may represent 
an alternative strategy for oedema control by steroids (e.g. 
dexamethasone) as corticosteroid therapy is associated with 
undesired off-target effects in the immune system [94] that 
may be counterintuitive in cancer immunotherapy.
Role of the BBB in glioma‑associated inflammation/
immune cell recruitment
The brain vasculature (BBB) not only controls the passage of 
metabolites but also controls leukocyte trafficking. Although 
the healthy brain restricts the trafficking of immune cells, in 
GBM immune cells are important constituents of the tumour 
microenvironment as they penetrate the dysfunctional GBM 
vasculature. The tumour pro-angiogenic vasculature thereby 
prevents the recruitment of tumour-reactive T lymphocytes 
and fosters an immunosuppressive microenvironment that 
allows gliomas to evade host immune-surveillance [84]. 
Sustained angiogenesis and immunosuppression are hall-
marks of cancer [46] and the abundance of tumour-associ-
ated macrophages (TAMs) has been associated with poor 
clinical outcome [98]. Macrophages secrete a plethora of 
cytokines and growth factors (among them VEGF) that 
contribute to tumour progression and vascular permeabil-
ity [98]. Myeloid-derived VEGF and signalling through 
VEGFR1 thereby contribute to GBM progression [58, 89]. 
Recently, Ang-2/Tie2 signalling has been linked to cancer 
inflammation as well as it promotes the recruitment of pro-
angiogenic, M2-polarised macrophages that contribute to 
therapy resistance [101, 106, 110]. Furthermore, a subpopu-
lation of macrophages in the perivascular tumour niche char-
acterised by Tie2 receptor expression known to contribute 
to tumour angiogenesis have recently been associated with 
the metastatic cascade [68]. In mammary tumours perivas-
cular macrophages promote the transient opening of tumour 
blood vessels by means or VEGF secretion to facilitate can-
cer cell dissemination (see [68]). These findings may in part 
explain the hyperpermeable nature of tumour vasculature 
that is described as spatially and temporally heterogeneous. 
Such findings may also translate to glioma where afore-
mentioned disturbances of the BBB are prominent in some 
regions (GBM core) while the NVU is functional in other 
regions (invasive zone) (Fig. 3a). Co-targeting of vascular 
integrity and pro-angiogenic, innate immune cells by angio-
genic inhibitors (VEGF, Ang-2) already showed improved 
therapeutic efficacy in GBM models [90, 106, 110]. A 
normalised vasculature is also permissive for the recruit-
ment of cytotoxic T lymphocytes thereby creating a tumour 
microenvironment that promotes anti-tumour targeting by 
cytotoxic T lymphocytes that secrete inflammatory cytokines 
upon combined anti-angiogenic and checkpoint therapy as 
recently shown in different tumour models including GBM 
[4, 108]. Similarly, Ang-2 and Tie2 co-targeting has been 
shown to be superior to either targeting Ang-2 (inhibi-
tion) and Tie2 (activation) alone as recently demonstrated 
by Park and colleagues [90]. A novel Ang-2-binding and 
Tie2-activating antibody (ABTAA) induced tumour vessels 
normalisation, reduced brain oedema, and changed innate 
immune cells towards an M1 phenotype in an orthotopic 
glioma model [90]. The glioma vessel normalisation fur-
ther enhanced intra-toumoral Temozolomide delivery [90]. 
Combined Tie2 activation and Ang-2 inhibition thus offers 
a novel therapeutic approach to elicit a favourable tumour 
microenvironment and enhance the delivery of chemothera-
peutics into tumours. The restoration of Tie2 signalling may 
also have implications for other disorders associated with 
defective BBB, i.e. stroke [43], epilepsy [11] and metas-
tasis whereby disease onset may be prevented by vascular 
stabilising agents.
Preventing brain metastasis by stabilising 
the blood–brain barrier
A rising incidence of brain metastases that commonly 
arise from cancers of the lung, breast and skin increase the 
demand for novel treatment to cure patients [98]. Tumour 
cells that have entered the bloodstream need to penetrate 
the BBB in order to get access to the brain parenchyma. The 
322 Acta Neuropathologica (2018) 135:311–336
1 3
partial disruption of the BBB leads to increased trespassing 
of molecules and cells and thereby potentially facilitating 
the colonisation of tumour cells into the brain. Treatment 
of mice with the neutralising Ang-2 peptibody Trebananib 
for instance has been shown to prevent changes in the BBB 
integrity and to inhibit breast cancer cell colonisation to the 
brain [8]. However, a heterogeneous blood–tumour barrier 
or BBB permeability determines the drug efficacy in experi-
mental brain metastases of breast cancer. Data from Lock-
man et al. indicate that the BBB remains partially intact in 
experimental brain metastases and thus impair drug delivery 
which demonstrates a need for brain permeable molecular 
therapeutics [73]. In this context, the impact of the BBB 
integrity for targeted therapy in different stages of brain 
metastases has recently been investigated [88]. The study 
suggests, that only drugs designed to fully penetrate the BBB 
are therapeutically efficacious [88].
On the other hand, interference with VEGFR1 signal-
ling inhibited monocytic cell migration into orthotopic 
brain tumours and subsequently slowed tumour growth 
[58, 89]. Of interest, a recent meta-analysis of clinical trials 
provided evidence that VEGF-inhibition is associated with 
fewer brain metastases in patients diagnosed with adeno-
carcinomas of the lung [54]. Therefore, it is of considerable 
interest to investigate whether the local destabilisation of the 
BBB acts as a prerequisite for successful formation of brain 
metastases by supporting the development of pre-metastatic 
perivascular niches and if so, whether the stabilisation of the 
BBB by pharmacological inhibitors is sufficient to prevent 
the formation of brain metastases.
Blood–Brain Barrier Dysfunction 
and Immune Cell Trafficking 
in neuroinflammation
Multiple sclerosis (MS) is the most common cause of non-
traumatic neurological disability affecting approximately 
2.5 million people worldwide. Although the pathogenesis 
leading to MS is not well understood, multiple studies have 
demonstrated the autoimmune nature of the disease in which 
self-reactive T cells specific for myelin proteins initiate an 
inflammatory cascade resulting in neuro-inflammation, 
demyelination and axonal damage [67]. The extensive het-
erogeneity in both disease course and pathological features 
seen in MS patients suggests that multiple pathways con-
tribute to disease pathogenesis. The majority of MS patients 
exhibit a relapsing–remitting disease course (RRMS) char-
acterised by the occurrence of focal inflammatory lesions 
within the CNS with a leaky BBB detectable by MRI and 
focal regions of demyelination [27].
The pathogenic mechanisms of MS have been extensively 
studied using the animal model experimental autoimmune 
encephalomyelitis (EAE), which is induced either by the 
activation or adoptive transfer of  CD4+ myelin-specific T 
cells. Among various immune cell subtypes,  CD4+ Th17 
(IL-17-producing) and Th1 (IFN-γ-producing) lymphocytes 
are the most prominent pathological immune cell types in 
both MS/EAE. These cells are distinguished by secretion 
of unique effector cytokines that have distinct effects in 
either promoting axonal damage and oligodendrocyte death 
or inducing BBB dysfunction [123]. The conventional 
Th17 cells generated in the presence of TGF-β1 and IL-6 
are non-pathogenic during EAE, since they are involved in 
the maintenance of mucosal surface homeostasis and anti-
bacterial defence. However, several inflammatory cytokines 
such as IL-1β, IL-23, and TGF-β3 promote generation and 
maintenance of highly pathogenic Th17 cells during EAE. 
These pathogenic Th17 cells express both RORγt and T-bet 
transcription factors, produce both IL-17A and IFN-γ and 
are preferentially recruited into the CNS (reviewed in detail 
in [115]). Other subsets of  CD4+ T cells, such as Th1 and 
Th9 also contribute to the development of neuro-inflam-
mation and autoimmunity. The adoptive transfer of MOG-
specific  CD4+ Th1 and Th9 cells induces EAE in C57BL/6 
recipients [34, 115]. Moreover, IL-9 is required for mast 
cell activation, which has been shown to degrade myelin 
during CNS inflammation [34]. While both Th1 and Th17 
effector  CD4+ T cell subsets are capable of inducing EAE in 
adoptive transfer studies, Th1 and Th17 cells show unique 
temporal profiles when they infiltrate the CNS during EAE. 
Th17 cells show the highest concentration in the spinal cord 
at 7 days post-immunisation and decrease to baseline by day 
10 in EAE. In contrast, Th1 lymphocytes are low at day 10 
and escalate in number in the EAE spinal cord by day 14 
[85]. Consistent with these observations, adoptive transfer 
of Th17 cells that are differentiated ex vivo induces more 
rapid clinical presentation of disease, as compared to adop-
tive transfer of Th1 cells differentiated ex vivo [105]. The 
potential explanation for these unique temporal features of 
CNS entry will be discussed below.
While the main emphasis has been placed on myelin-
specific  CD4+ T cells in MS/EAE pathogenesis, recent 
studies suggest that neutrophils are also critical for disease. 
In EAE, neutrophils comprise a significant percentage of 
CNS-infiltrating cells prior to disease onset and relapse [91]. 
When neutrophils are depleted prior to, but not after, there 
is an improvement in disease onset or relapse, suggesting 
that neutrophil function is important during the initial for-
mation of lesions [111]. Neutrophils in the blood of RRMS 
patients exhibit a primed phenotype, and both their number 
and activity increase during relapses. Similarly, MS patients 
have a higher neutrophil-to-lymphocyte ratio in the blood 
compared to healthy controls, and the ratio increases with 
the occurrence of relapse and worsening disability [111]. 
However, neutrophils are not a pronounced feature of CNS 
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pathology in MS patients. One potential explanation is that 
neutrophils have a short half-life and may only contribute 
to disease at specific stages, i.e. prior to onset or relapses. 
Nevertheless, they play an important role in the initial BBB 
dysfunction [7] (see below).
Mechanisms of immune cell interactions 
with the CNS vasculature in neuro‑inflammation
In MS and EAE, leukocytes or other immune cells migrate 
across multiple pathways to reach the CNS parenchyma, 
including the BBB and choroid plexus. The transmigration 
across the BBB is a very dynamic process and depends on 
several sequential, yet interdependent steps constituting (1) 
tethering, (2) rolling, (3) crawling, (4) arrest, (5) diapede-
sis of immune cells across the ECs and (6) destruction of 
the basal lamina [20]. Leukocytes may also infiltrate the 
CNS via the blood–cerebrospinal fluid route through an epi-
thelial barrier present within the choroid plexus. Intravital 
microscopy analysis of encephalitogenic T cell interactions 
with inflamed brain and spinal cord microvessels has shown 
that interactions of P-selectin glycoprotein ligand (PSGL-1) 
with P/E-selectin mediates the initial rolling and tethering 
of T cells [59]. However, deficiencies in E- and P-selec-
tin or PSGL-1 do not protect mice from EAE, suggesting 
redundant roles for these proteins in neuro-inflammation 
[31]. Inflamed CNS endothelial cells upregulate expres-
sion of both the intercellular adhesion molecule 1 (ICAM-
1) and vascular cell adhesion molecule 1 (VCAM-1). The 
respective ligands, αLβ2 [lymphocyte function-associated 
antigen 1 (LFA-1)], and α4β1 [very late antigen 4 (VLA-
4)] integrins, are expressed on encephalitogenic  CD4+ T 
cells. Multiple studies have shown that LFA-1-ICAM-1 and 
VLA-4-VCAM-1 interactions are critically involved in the 
firm arrest of  CD4+ T cells onto the inflamed CNS vessels 
or primary brain EC monolayers [20]. Moreover, LFA-1-
ICAM-1 interactions dictate the polarisation and crawling of 
 CD4+ T cells onto the inflamed CNS vessels. Interestingly, 
α4β1-integrin-VCAM-1 interaction preferentially arrests 
encephalitogenic Th1 cells onto the spinal cord blood vessels 
suggesting that Th1 cells preferentially use α4-integrin for 
transmigration across the BBB [105]. The anti-α4-integrin 
antibody, natalizumab has been approved for the treatment 
of relapsing–remitting MS suggesting that the arrest step is 
critical for disease pathogenesis. However, live cell imaging 
studies of transendothelial migration across ICAM-1 and 
ICAM-2-deficient brain endothelial monolayers have shown 
that  CD4+ T cell may undergo diapedesis in an ICAM-inde-
pendent manner [1], suggesting that other adhesion mol-
ecules may function in a redundant manner.
Additional cell adhesion molecules such as activated leu-
kocyte cell adhesion molecule (ALCAM) and melanoma cell 
adhesion molecule (MCAM) also control transmigration of 
the  CD4+ and  CD8+ T cells across the BBB and CNS auto-
immunity [22, 65]. Th17 autoreactive T cells express very 
high levels of MCAM and antibody-mediated blockade of 
MCAM reduces CNS autoimmunity [65]. Antibody-medi-
ated inhibition of ALCAM reduced diapedesis of human 
 CD4+ Th1 but not of Th17 cells across a human BBB 
in vitro. However, ALCAM play a significant role in rolling, 
adhesion, and diapedesis of human monocytes across the 
human BBB suggesting that distinct cell adhesion molecules 
may contribute to selective interactions of distinct classes of 
immune cells with the inflamed CNS endothelium in neu-
roinflammation [69]. ALCAM deficient mice developed a 
more severe EAE due to a reduced expression of BBB junc-
tional proteins. ALCAM is associated with the assembly of 
tight junction molecules that explains the increased perme-
ability of CNS blood vessels in mutant animals [69]. There-
fore, ALCAM may also function to maintain BBB integrity.
Once arrested,  CD4+ T cells start crawling on inflamed 
CNS microvessels to search for sites of diapedesis. Immune 
cells can cross the BBB through migration via the paracellu-
lar route due to breakdown of EC tight junctions (TJs) or the 
transcellular route, mediated by an increase in the number 
of caveolar vesicles that transport cells and large molecules 
including antibodies across CNS blood vessels [42]. How is 
Th17 versus Th1  CD4+ T cell trafficking across a dysfunc-
tional neurovascular barrier coordinated with degradation 
of tight junctions and increased caveolar transcytosis during 
MS/EAE? Previous studies have shown that Th17 cells show 
the highest concentration in the spinal cord at 7 days post-
immunisation that decreases to baseline by day 10 in EAE. 
In contrast, Th1 lymphocytes are low at day 10 and escalate 
in number in the EAE spinal cord at day 14 [85]. We have 
recently found that caveolin-1 (Cav-1), a protein essential 
for the formation of caveolae, is not required for either tight 
junction degradation at the BBB or early development of 
clinical EAE; however, it is required for transmigration of a 
subset of Th1 cells across the BBB [76]. Why do Th1 lym-
phocytes preferentially cross the BBB via caveolae in EAE? 
Cell adhesion molecules such as ICAM-1/2 and VCAM-1 
are enriched in caveolae and support transcellular migra-
tion of immune cells by engaging infiltrating cell podocytes 
[1, 20]. Upon attachment of the  CD4+ T cells to the apical 
surface of inflamed brain ECs, ICAM-1 and VCAM-1 are 
clustered around transmigrating  CD4+ T cells, resulting in 
the formation of caveolae enriched with actin filaments [1, 
20]. Increased levels of ICAM-1 on the apical surface of 
primary mouse brain microvascular cell monolayers may 
promote transcellular migration of  CD4+ T cells possibly 
because of high occupancy of its receptor LFA-1 on  CD4+ T 
cells [1, 20]. Th17 cells rely primarily on an αLβ2/ICAM-1 
interaction [105, 123], whereas Th1 cells employ an α4/
VCAM-1 complex for their migration [41]. Thus, selective 
interactions between these adhesion molecules may direct 
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Th1 cells more effectively toward caveolae as compared to 
Th17 when crossing the CNS vessels in neuro-inflammation.
Other cell adhesion and junction proteins such as 
PECAM-1, CD99, claudin-5, VE-cadherin, VE-PTP and 
JAMs have been shown to play an important role in regu-
lation of paracellular migration across the BBB. CD99 is 
a crucial regulator of diapedesis of leukocytes through the 
blood vessel wall. Genetic inactivation of CD99 causes 
neutrophil accumulation between endothelial cells and the 
basement membrane in inflamed peripheral post capillary 
venules and impaired leukocyte attachment to the luminal 
surface of the vessel [42]. CD99 promotes leukocyte attach-
ment to the endothelium in inflamed vessels by a hetero-
philic ligand. In addition, CD99 binds to the paired immu-
noglobulin-like receptors (PILRs) on neutrophils to increase 
the shear resistance of the neutrophil attachment to ICAM-1 
[42]. CD99 can also interact with PECAM-1 to promote 
immune cell migration across the blood vessels. Blockade 
of CD99 or CD99L2 function, or genetic inactivation of 
PECAM-1 traps neutrophils between endothelial cells and 
the underlying basement membrane in vivo in the inflamed 
peripheral blood vessels. CD99 is also critical for lympho-
cyte transmigration across a human BBB model in vitro. 
Blocking CD99 in vivo ameliorates EAE and decreases the 
accumulation of CNS inflammatory infiltrates, including 
dendritic cells, B and T cells. Anti-CD99 therapy is effec-
tive to block relapse when administered therapeutically 
after disease symptoms had recurred [135]. These findings 
indicate an important role for CD99 in the pathogenesis of 
CNS autoimmunity and suggest that it may serve as a novel 
therapeutic target for controlling neuro-inflammation. CD99, 
PECAM-1 and VE-cadherin are enriched in an endothelial-
specific subcellular compartment called the lateral border 
recycling compartment. The lateral border recycling com-
partment has been proposed to function as the subcellular 
organelle where rapid remodelling of cell junctional proteins 
happens in brain ECs as they interact with transmigrating 
monocytes in vitro [136]. These organelles may be homolo-
gous to dynamic TJ protrusions that several groups have 
observed by two photon imaging in either epithelial cells 
of the gut [78] or endothelial cells in the brain [62] and 
spinal cord (Fig. 4) under inflammatory conditions. This 
compartment has been shown to support both paracellular 
and transcellular migration in vitro; however, it is unclear 
if it this compartment has any role in transmigration across 
the BBB in vivo.
During inflammation, activated T cells can cross the 
endothelial basement membrane, but additional signals are 
required to break down the glia limitans to allow leuko-
cytes to infiltrate the CNS parenchyma. After crossing the 
endothelial vessels of the BBB,  CD4+ T cells encounter the 
glial (glia limitans) basement membrane, and breaching this 
acellular structure represents a challenge for  CD4+ T cells to 
arrive at the CNS. The endothelial basement membrane at 
the BBB is characterised by the presence of both laminin α4 
and α5. Encephalitogenic  CD4+ T cells cross the endothelial 
basement membrane through α6β1-integrin-laminin α4 inter-
actions, whereas laminin α5 inhibits their migration [115]. 
In contrast to the endothelial basement membrane, the glia 
limitans is enriched with laminin α1 and α2. Since encepha-
litogenic  CD4+ T cells do not interact with laminin α1 and 
α2, they depend on secretion of matrix metalloproteinases 
(MMPs) to degrade this basement membrane in order to 
enter the CNS. It is hypothesised that matrix metalloprotein-
ases (MMPs) secreted by neutrophils contribute to this step 
in the pathogenesis of MS. Various types of MMPs, such as 
MMP-2, -7, -8, and -9, have been identified in the CSF and 
MS/EAE lesions. MMP2 and MMP9 expression are specifi-
cally increased during EAE, and their activity is positively 
correlated with the migration of  CD4+ T cells across the 
glia limitans (see [91] for more details). One of the MMP2/9 
targets is β-dystroglycan, a receptor which anchors astrocytic 
endfeet to the parenchymal basement membrane, leading to 
secretion of chemokines by the astrocytes at the glia limi-
tans. Therefore, neutrophils may specifically alter the glia 
limitans to promote the final step of  CD4+ T cell entry into 
the CNS in neuro-inflammation [91].
How do immune cells affect the blood–brain barrier 
in neuro‑inflammation
Several TJ proteins such as claudin-3, -5, -12 and occludin, 
that normally restrict paracellular movement of molecules 
across the BBB, are disrupted in neuro-inflammatory dis-
eases including MS/EAE. Endothelial TJ degradation pre-
cedes overt lesion formation in MS, correlates with clini-
cal EAE severity and promotes leukocyte migration via the 
paracellular route [6, 38]. On the contrary, overexpression 
of the TJ-associated protein claudin-1 is protective for EAE 
(see [35]). TJs are highly dynamic in vivo and their rate of 
turnover is increased after inflammation in both gut epithe-
lial cells and brain EC following ischaemic stroke or EAE 
[62, 76, 78]. Although BBB disruption promotes neuro-
inflammation by enabling inflammatory proteins, antibodies 
and leukocytes to access the CNS, it has remained elusive 
how dynamic remodelling of EC TJs regulates immune cell 
trafficking into the CNS during EAE progression. We have 
recently shown using intravital two-photon microscopy in 
Tg eGFP-Claudin5+/− mice, in which EC TJs are labelled 
with enhanced green fluorescent protein (eGFP) to visualise 
dynamic changes in TJs during EAE that dynamic remod-
elling of TJs and paracellular BBB leakage increase prior 
to the onset of EAE and remain high throughout disease 
(Fig. 4b) [76].
In addition to the presence of TJs, BBB permeability 
is also controlled via non-clathrin-coated caveolae that 
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are highly enriched in Cav-1. The density of endocytotic 
vesicles within CNS endothelium and the expression of 
Cav-1 increase during acute MS/EAE [76], suggesting that 
endothelial caveolae may provide a migratory route for mye-
lin-specific T cells into the CNS (Fig. 4b). Caveolae cluster 
adhesion molecules are essential for interactions between 
immune cells and endothelium [20]; moreover, they also 
regulate turnover of TJ proteins in both epithelial and ECs 
in vitro induced by inflammatory cytokines [78, 119]. These 
studies suggest that caveolae may play an essential role in 
Fig. 4  Schematic presentation of BBB breakdown and lymphocyte 
trafficking across a damaged BBB in neuroinflammation. a Trans-
genic mice that allow visualisation of endothelial tight junctions 
(Tg eGFP::Claudin-5) with intravital two-photon microscopy. The 
image shows cortical blood vessels that have eGFP in tight junctions 
(green). Biocytin-TMR tracer (red) was injected into the tail vein of 
mice to visualise the vascular tree. This tracer also allows measure-
ment of BBB permeability. b A working model of BBB disruption 
during EAE. Increased paracellular BBB permeability (green line) 
occurs prior to onset and persists throughout EAE. Transcellular BBB 
permeability (red line) only transiently elevates at acute disease. Para-
cellular permeability is due to rapid remodelling of TJ proteins, while 
transcellular permeability results from enhanced caveolar trafficking. 
c During the early phase of MS/EAE progression, there is an initial 
breakdown of endothelial cells TJs at the BBB that causes an increase 
in paracellular permeability. This allows the preferential entry of 
Th17 lymphocytes (blue) in the early phase of the disease, although 
some Th1 lymphocytes (purple) also enter through this route. b The 
increase in caveolar transport (transcellular permeability) through 
upregulation of Caveolin-1 is observed only during the late phase of 
neuroinflammation at the peak of the disease. Th1 lymphocytes (pur-
ple) preferentially use caveolae to cross the BBB through enhance 
transcellular permeability. TJ remodelling in both phases of the dis-
ease involves formation of membrane invaginations (protrusions) that 
fuse with  EEA1+ endosomes. However, TJ remodelling is independ-
ent of caveolae suggesting that in MS/EAE, similar to BBB develop-
ment, there are distinct mechanisms that impair paracellular versus 
transcellular barrier properties of the CNS vasculature
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EAE pathology by orchestrating both TJ degradation and 
paracellular migration of immune cells across the BBB as 
well as promoting adhesion and migration of immune cells 
via the transcellular route. In support of this hypothesis, 
mice lacking Cav-1, a protein essential for caveolae forma-
tion, are protected from EAE and develop minimal clinical 
manifestations with very few  CD4+ T cells infiltrations into 
the CNS [138]. However, dynamic remodelling of TJs at the 
neuro-vasculature is not changed in Cav-1−/− mice during 
EAE progression, suggesting that caveolae do not play a 
role in remodelling of EC junctions in EAE. Moreover, Cav-
1−/− mice have a selective decrease in the number of Th1, 
but not Th17 lymphocytes in the CNS. Therefore, caveolae-
independent remodelling of TJs facilitates Th17 lympho-
cyte transmigration across the BBB in neuro-inflammation, 
whereas caveolae regulate the entry of Th1 lymphocytes into 
the CNS (Fig. 4c) [76].
What controls TJ remodelling and degradation during 
inflammation in vivo? Caveolae have been proposed to pro-
mote TJ endocytosis in both CNS and non-CNS ECs in vitro, 
as well as in non-CNS ECs in vivo [78, 119]. We have found 
that dynamic TJ protrusions are highly prevalent prior to 
EAE onset consistent with the proposed role for neutro-
phils in promoting early BBB breakdown by secretion of 
proteolytic enzymes (Fig. 4b) [41, 91]. In EAE, an increase 
in BBB permeability is associated with the early influx of 
neutrophils into the CNS. Depletion of neutrophils helps 
preserve BBB integrity, suggesting that neutrophils play a 
role in early BBB breakdown [91]. Neutrophils have also 
been correlated with BBB leakage in an acute MS lesion and 
their presence correlates with observations of dynamic TJ 
protrusions at the BBB prior to disease onset. Although the 
exact mechanisms of neutrophil-mediated BBB breakdown 
are still unknown, it is hypothesised that matrix metallopro-
teinases (MMPs) secreted by neutrophils contribute to this 
step of disease pathogenesis [91].
Another potential mechanism that may control the rate 
of TJ degradation in CNS ECs could be an enhanced endo-
cytotic or macro-pinocytotic remodelling/degradation of 
junctional proteins in response to inflammatory cytokines 
secreted by immune cells or microglia that are present in 
EAE. IL-17 and IL-22 cytokines produced by Th17 cells 
disrupt BBB tight junctions in vitro and in vivo [57]. IL-
17A induces NADPH oxidase- or xanthine oxidase-depend-
ent reactive oxygen species (ROS) production that in turn 
activates myosin light chain kinase (MLCK) leading to 
down-regulation of occludin [52]. Blocking either ROS 
formation, myosin light chain phosphorylation, or applying 
IL-17A-neutralising antibodies prevents IL-17A-induced 
BBB disruption [52]. Treatment of EAE mice with ML-7, 
an MLCK inhibitor, results in reduced BBB disruption at 
the spinal cord and lymphocyte infiltration and is associ-
ated with reduced clinical characteristics of EAE [52]. 
Encephalitogenic  CD4+ Th17 cells can also indirectly break-
down the BBB. Th17 cells induce expression of CXCL1 and 
CXCL2 in the spinal cords which are two chemokines that 
promote BBB breakdown via mobilisation of polymorpho-
nuclear leukocytes (PMN) [19].
Th1  CD4+ T cells also have a negative impact on BBB 
function. cells IFN-γ, a cytokine predominantly produced 
by Th1 T cells, increases expression of ICAM-1, VCAM-1, 
MAdCAM-1, H2-Kb and I-Ab molecules on brain endothe-
lial cells and induces transendothelial migration of  CD4+ T 
cells from the apical (luminal) to the basal (abluminal) side 
of the endothelial monolayer. IFN-γ favours the transcellu-
lar route of  CD4+ T cells migration by promoting caveolar 
transport [116]. In culture, IFN-γ induces internalisation 
and re-localization of VE-cadherin, PECAM-1, ZO-1 and 
Claudin-5 in the endothelial cells, which affects the migra-
tion of  CD4+ T cells. IFN-γ produced during inflammation 
could contribute towards disrupting the BBB and promot-
ing transendothelial migration of  CD4+ T cells [116]. The 
inflammatory cytokines IL-1β and TNF-α and CCL2 are 
elevated in the acute phase of MS and EAE and can enhance 
paracellular barrier permeability [14]. CCL2 has been shown 
to promote degradation of claudin-5 in a Cav-1-dependent 
manner in brain ECs in vitro [119].
Finally, matrix metalloproteinases (MMPs) secreted by 
neutrophils also contribute to BBB damage during MS/
EAE pathogenesis. The activity and expression of MMP-9 
is increased in serum, CSF, and active lesions in MS and 
has been associated with BBB breakdown in mice. MMP-9 
can damage several BBB proteins such as adherens and 
tight junctions. Neutrophils can also produce ROS, which 
is known to disrupt junctional proteins of the BBB endothe-
lium, leading to increased permeability.
Blood–brain barrier pathology 
in Alzheimer’s disease
Alzheimer’s disease (AD) is a chronic neurodegenerative 
disorder characterised by neuronal degeneration, gliosis, and 
amyloid beta (Aβ) accumulation, leading to cerebral amyloid 
angiopathy (CAA), senile plaque formation and the develop-
ment of neurofibrillary tangles containing hyperphosphoryl-
ated neuronal tau protein [99]. AD pathology is also charac-
terised by chronic brain inflammation, with microglial cells 
implicated in the accumulation of Aβ and neuronal damage 
[47].
BBB dysfunction also contributes to the onset and pro-
gression of AD [83, 143]. For example, BBB transport sys-
tems are significantly altered in AD patients compared to 
controls [83]. The glucose transporter GLUT1 is expressed 
at a lower level in the brain capillaries of AD patients and 
mouse models of AD, and GLUT1 deficiency leads in ECs 
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leads to the loss of TJ proteins and BBB dysfunction in 
mouse models of AD [81, 83]. Glucose uptake at the BBB is 
disrupted in patients with mild cognitive impairment (MCI) 
and this may precede neurodegeneration and conversion to 
AD [83]. The expression of Aβ peptide transporters in ECs 
also changes during AD [149]. The expression of low-den-
sity lipoprotein receptor related protein 1 (LRP1), which 
mediates the efflux of Aβ from the brain to the periphery, 
is significantly reduced in the brain ECs of AD patients, 
whereas the expression of endothelial RAGE increases, pro-
moting Aβ influx back into the CNS and favouring Aβ accu-
mulation in the brain [83]. Aβ oligomers can directly induce 
the expression of RAGE in ECs, further contributing to the 
altered expression and function of Aβ transporters [83].
Aβ is a major contributor to BBB dysfunction in AD and 
Aβ deposits in the vasculature enhance BBB permeability 
in the AD brain. Previous studies have shown that CAA pro-
motes the degeneration of smooth muscle cells, pericytes 
and ECs, leading to BBB breakdown [36]. Aβ disrupts TJs 
and increases vascular permeability by inhibiting the expres-
sion of TJ proteins and inducing the expression of matrix 
metalloproteases (MMPs), which may in turn degrade TJ 
components [63, 131]. Furthermore, the expression of TJ 
proteins is significantly lower in patients with capillary 
CAA, leading to increased vascular permeability in the AD 
brain [21]. Experimental evidence suggests that tau pathol-
ogy also disrupts the integrity of the BBB, thus both tau and 
Aβ may induce BBB dysfunction, promoting neurodegenera-
tion and cognitive impairment [13].
Changes in the extracellular matrix (ECM) that forms the 
BBB basement membranes are also observed in AD patients, 
suggesting they may contribute to BBB dysfunction in AD 
[143]. MMPs such as MMP-3 and MMP-9 are more abun-
dant in the cerebrospinal fluid (CSF) of AD patients than 
controls, and may be responsible for ECM degradation at 
the BBB level in AD [121]. Secreted MMPs can digest the 
endothelial basal lamina and TJ scaffold proteins, which are 
necessary for BBB integrity, and may lead to BBB injury in 
AD. Furthermore, Aβ1-42 oligomers induce the expression 
of MMP-2 and MMP-9 in brain ECs, and MMPs released by 
ECs may contribute to basement membrane degradation and 
BBB dysfunction [131]. Pathological changes in the struc-
ture and organization of basement membrane ECM proteins 
may favour the migration of circulating leukocytes, which 
represent a key inflammatory process in AD [143, 144].
Cellular components of the neurovascular unit (NVU), 
such as pericytes and glial cells, may also contribute to BBB 
permeability in AD. Recent studies have shown that AD 
patients lose significant numbers of pericytes in the cor-
tex and hippocampus compared to controls, suggesting that 
pericyte dysfunction contributes to BBB disintegration in 
AD (for review see [83]). Pericyte deficiency leads to BBB 
damage, cognitive impairment, increased Aβ deposition 
and tau pathology, further suggesting a predominant role 
of pericyte dysfunction in AD pathogenesis (for review see 
[83]). The expression of APOE4 (a major genetic risk fac-
tor for AD), but not APOE3, leads to pericyte loss in AD, 
which correlates with the magnitude of BBB degradation 
to plasma proteins [44]. Recent studies have shown higher 
CSF levels of soluble platelet-derived growth factor receptor 
β (sPDGFRβ), a marker of pericyte injury, correlating with 
increased BBB permeability in the hippocampus of MCI 
patients compared to controls, indicating that pericyte dam-
age is a key mechanism leading to cognitive impairment (for 
review see [83]).
Most of the glial cells surrounding the parenchymal basal 
membrane of brain microvessels are astrocytes, and their 
dysfunction may also contribute to BBB breakdown in AD. 
Changes in astrocyte morphology have been observed near 
blood vessels with Aβ deposits in the AD brain, whereas 
experimental studies have shown the retraction and swell-
ing of astrocyte endfeet surrounding vascular Aβ deposits 
and the downregulation of GLUT1 and lactate transporter 
expression [81]. Aβ pathology disrupts the perivascular 
sheath of astrocyte processes by reallocating AQP4, and this 
may induce astrocyte depolarization [141]. During inflam-
matory responses, astrocytes may secrete several types 
of cytokines and chemokines, such as interleukin (IL)-1, 
CXCL1, IL-6, IL-8 (CXCL8), monocyte chemoattractant 
protein 1 (MCP-1/CCL2), interferon gamma-induced pro-
tein 10 (IP-10/CXCL10) and macrophage inflammatory pro-
tein 1 alpha (MIP-1β/CCL3), which may attract circulating 
leukocytes inside the brain and fuel a chronic inflamma-
tory process. Activated perivascular microglial cells may 
also secrete a plethora of inflammatory mediators includ-
ing cytokines and chemokines, and may actively promote 
neuroinflammation and leukocyte recruitment into the AD 
brain [143].
Vascular inflammation in the context of an altered BBB 
has been implicated in the pathogenesis of AD [92, 93, 
143, 144] (Fig. 5). Brain endothelial inflammation leads to 
the expression of two main classes of adhesion molecules: 
endothelial selectins such as E-selectin and P-selectin, and 
integrin ligands such as ICAM-1 and VCAM-1 from the Ig 
superfamily, which bind the LFA-1 and very late antigen 4 
(VLA-4) integrins, respectively. During brain inflammation, 
ECs express adhesion molecules, which are also released in 
the bloodstream, providing biomarkers of vascular inflam-
mation and BBB dysfunction. Soluble VCAM-1, ICAM-1, 
E-selectin and P-selectin were expressed at higher levels in 
plasma samples from AD patients compared to controls, sug-
gesting that brain ECs are inflamed in AD [143]. For exam-
ple, elevated levels of soluble VCAM-1 in the plasma of AD 
patients correlate with the severity of dementia and brain 
changes observed by magnetic resonance imaging (MRI) 
[143]. Interestingly, soluble adhesion molecules are also 
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serum markers of inflammation and endothelial dysfunction 
associated with ageing, suggesting they may also represent 
a marker of age-dependent cognitive decline. Therefore, 
increased levels of soluble endothelial adhesion molecules 
may provide biomarkers of vascular inflammation and dis-
ease severity in AD.
Aβ peptides may directly activate ECs, inducing the 
expression of ICAM-1 and VCAM-1 and endothelial 
Fig. 5  Schematic representation of BBB alterations and leukocyte 
extravasation in postcapillary venules in the AD brain. Endothe-
lial cells are the first barrier between blood leukocytes and the brain 
parenchyma. Endothelial cells are linked by tight junctions closely 
surrounded by pericytes and encircled by the endothelial basal lam-
ina (brown line) and parenchymal basement membrane (violet line). 
Astrocyte endfeet processes support endothelial functions and provide 
the cellular link to neuronal cells. Aβ and other inflammatory stimuli 
promote the activation of vascular endothelium, potentially inducing 
the expression of adhesion molecules and chemoattractants. The acti-
vated endothelium promotes the adhesion of neutrophils and even-
tually other circulating leukocytes that transmigrate into the brain 
parenchyma. Neutrophils adhered on the activated endothelium may 
release neutrophil extracellular traps (NETs) comprising decondensed 
chromatin and active proteases, which damage the BBB. Migrated 
neutrophils release inflammatory mediators and NETs, and may dam-
age neurons. Neutrophils and glial cells may become trapped in a 
cycle of reciprocal activation, promoting chronic inflammation and 
neurodegeneration
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selectins, suggesting these molecules may promote leu-
kocyte adhesion and transmigration during AD (Fig. 5). 
Accordingly, the expression of E-selectin, P-selectin, 
VCAM-1 and ICAM-1 is significantly higher in the brain 
vessels of transgenic animals with both Aβ and tau pathol-
ogy compared to wild-type controls [144]. These adhesion 
molecules were expressed mainly in the brain vessels of 
the cortex, hippocampus, amygdala, meninges and choroid 
plexi of the AD mice [144]. However, it is unclear whether 
endothelial adhesion molecules are expressed at the BBB 
level in AD patients and further neuropathological studies 
are needed to clarify this key aspect of BBB dysfunction and 
brain inflammation.
Circulating leukocyte subpopulations, including mono-
cytes, neutrophils and lymphocytes, have been identified 
in the brains of patients with AD and in transgenic ani-
mals with AD-like disease. Blood monocytes can migrate 
through the BBB into the brains of mice with AD-like dis-
ease using chemokine receptor CCR2 [87]. CCL2, the main 
CCR2 ligand, is expressed in the microvessels of AD-like 
mouse brains and the post-mortem brains of AD patients, 
suggesting it may also play a role in monocyte recruitment 
during human AD [87]. Several reports have indicated that 
migrating monocytes are beneficial in AD by promoting 
the clearance of Aβ (see [87]). However, more recent stud-
ies have challenged this view by showing that monocytes 
do not reduce the amyloid load, arguing against a role for 
circulating monocytes in Aβ clearance [97]. It is not yet 
known whether monocyte recruitment into the brain plays a 
role during the pathogenesis of human AD. Neutrophils can 
also migrate in the brains of AD patients and transgenic ani-
mals with AD-like disease [92, 93, 143, 144] (Fig. 5). These 
highly reactive cells do not need to accumulate in large num-
bers to induce substantial tissue damage, and may release 
a myriad of pro-inflammatory mediators including reactive 
oxygen species, enzymes and cytokines. Neutrophils may 
also release neutrophil extracellular traps (NETs), which 
can cause substantial tissue damage during inflammatory 
diseases [92, 93, 143, 144]. Recent studies have shown that 
neutrophils play a role in the induction of cognitive deficit 
and neuropathological changes in transgenic mice develop-
ing Aβ and tau pathologies [92, 93, 143, 144]. Neutrophils 
adhere inside blood vessels and migrate into the parenchyma 
in rodent AD models and human AD patients, whereas in 
controls these cells do not gain access to the CNS (Fig. 5). 
Intravascular and intra-parenchymal neutrophils also pro-
duce NETs in rodent AD models and human AD patients, 
suggesting these cells may induce BBB damage and harm 
neural cells. Interestingly, neutrophils adhere and spread 
inside blood vessels with Aβ deposits and migrate into the 
parenchyma in areas rich of with Aβ, supporting a role for 
Aβ in neutrophil recruitment in the AD brain (Fig. 5) [92, 
93, 143, 144]. Soluble oligomeric Aβ1-42 induces the rapid, 
integrin-dependent adhesion of both human and mouse neu-
trophils on integrin ligands, triggering the LFA-1 integrin 
high-affinity state. These data suggest that vascular Aβ may 
favour neutrophil adhesion on brain ECs and may promote 
neutrophil-dependent BBB damage (Fig. 5). Therapeutic 
blocking of LFA-1 integrin rescues memory and reduces the 
severity of neuropathological changes in AD models, sug-
gesting that interfering with the molecular mechanisms con-
trolling leukocyte adhesion and migration inside the brain 
parenchyma may offer a new therapeutic strategy in AD.
CD4+ and  CD8+ T cells can also adhere in brain ves-
sels and migrate into the parenchyma in AD patients [143]. 
In agreement with these observations, patients with mild 
AD or MCI have greater numbers of activated  CD4+ and 
 CD8+ T cells in the CSF compared to controls, suggest-
ing that lymphocytes with an activated phenotype can cross 
CNS barriers and contribute to disease pathogenesis [75]. 
In mouse models of Aβ pathology, T cells also infiltrate the 
brain and secrete interferon gamma (IFNγ) or IL-17, sug-
gesting that lymphocyte cytokines may activate microglial 
cells and directly harm the BBB and neurons, promoting 
AD neuropathology. Peripheral inflammatory processes may 
activate T cells, promoting their translocation from the blood 
compartment into the brain, which may in turn contribute to 
AD pathology. In transgenic rodent models of Aβ pathology, 
the lack of lymphocytes reduces Aβ deposition enhances 
microglial activation and the phagocytosis of Aβ aggregates, 
suggesting that lymphocyte recruitment into the CNS may 
play a negative role in AD [118]. It remains unclear how T 
cells gain access through the BBB or other CNS barriers 
into the AD brain. Previous studies suggest that Aβ deposits, 
transforming growth factor β (TGF-β) and the expression of 
vascular adhesion molecules and chemoattractants may play 
a role in lymphocyte migration into the AD brain. As sug-
gested for neutrophils, Aβ deposits promote T cell accumula-
tion in the brain, presumably via the activation of brain ECs 
and the induction of vascular adhesion molecule expression 
[40]. Aβ1-42 induces the release of cytokines by microglial 
cells, which in turn promotes the trans-endothelial migration 
of T cells in vitro, whereas T cells were found in leptome-
ningeal and cortical vessels associated with CAA, suggest-
ing that Aβ favours T cell migration into the AD brain [16, 
140]. Furthermore, the injection of Aβ into the hippocampus 
activates ECs and promotes T cell migration into the brain 
[70]. TGF-β1 supports T cell infiltration in the meninges 
and brain parenchyma in mice immunised with Aβ1-42, but 
the role of this molecule in the neuro-inflammation associ-
ated with AD is still unclear [143]. Peripheral T cells in 
AD patients overexpress MIP-1α [77]. This may bind to its 
receptor CCR5, which is highly expressed on brain ECs in 
aged AD patients, providing supporting evidence for T cell 
migration through endothelial TJs into the CNS [77, 82].
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Concluding remarks
Since the concept and the cellular identity of the BBB have 
been established about 100 and 50 years ago, respectively, 
there has been considerable progress in understanding 
the molecular composition and genetic as well as to some 
extent epigenetic regulation. Specifically, the identifica-
tion of pathways like Wnt/β-catenin, Shh, retinoic acid, 
angiopoietins and others, involved in regulation of barrier 
properties during embryonic and postnatal development as 
well as barrier maintenance, has provided novel insight into 
BBB characteristics. Moreover, these pathways offer novel 
strategies to mimic BBB function in single- and co-culture 
in vitro models and, none the less, novel targets for pharma-
cological opening or closing of the BBB under pathological 
conditions.
Nevertheless, many aspects of BBB dysfunction after 
stroke, in brain tumours, chronic inflammation and Alzhei-
mer’s disease remain unknown. Future studies should aim 
to further elucidate the causes and consequences of BBB 
disruption, particularly with regard to the close interaction 
between neuronal, glial, PCs and ECs—i.e. the NVU—as 
well as inflammatory cells. In general, acute and chronic 
inflammation appears to be a hallmark of CNS pathology, 
requiring a re-adjustment of defining the concept that the 
CNS is an immune-privileged organ. In fact, targeting the 
immune response directly or indirectly by small-molecules 
or antibodies that cross the BBB may have beneficial effects 
by preventing for example cancer oedema, favouring Aβ 
clearance and decreasing chronic neuro-inflammation. In 
this context, the characterization of adhesion molecules and 
chemoattractants controlling vascular inflammation, as well 
as pathway that might be exploited to seal the BBB such as 
Wnt/β-catenin, Shh, retinoic acid, angiopoietins, etc. will 
be a highly relevant task in the future. Hence, combining 
multiparametric imaging information, (causal) relationships 
between BBB dysfunction and other (patho)biological fac-
tors, will enable original translational studies in experimen-
tal and clinical settings that will increase our understanding 
of the critical role of the BBB in brain pathology and recov-
ery, ultimately contributing to improved patient care.
In conclusion, understanding the healthy BBB with its 
cellular and molecular players will be a prerequisite for 
transferring the knowledge to targeted therapy of CNS 
pathologies. Studies of recent years have shown that the 
BBB and the NVU in particular, is even more complex and 
diverse in specific regions of the CNs with regard to cellular 
and molecular interactions. The characterization of molecu-
lar mechanisms leading to BBB dysfunction and of common 
and diverse aspects of BBB function in the CNS will help 
to specifically modulated barrier characteristics on demand 
for the adjunct treatment of fatal diseases like stroke, brain 
tumour, chronic inflammation and Alzheimer’s disease.
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